Search results for "graft survival"

showing 10 items of 88 documents

Ten Years of Simultaneous Pancreas-Kidney Transplantation: A Retrospective Single-Center Analysis of Prospectively Obtained Data

2011

Simultaneous pancreas-kidney transplantation (SPK) is a standardized and life-saving procedure for a patient suffering from both insulin-dependent diabetes mellitus type 1 (IDDM 1) and end-stage diabetic nephropathy. To expand the donor pool and to determine the influence of the preprocurement pancreas suitability scoring system (P-PASS) on pancreas graft survival we retrospectively analyzed our data on SPK.From 1999 to 2010 we performed 55 SPKs, using systemic-enteric drainage as surgical approach. The immunosuppressive therapy was induced with basiliximab; maintenance therapy was based on tacrolimus, mycophenolate mofetil, and steroids. Data were prospectively obtained, analyzed, and corr…

AdultGraft RejectionMalemedicine.medical_specialtyScoring systemCell SurvivalSingle CenterBody Mass IndexDiabetic nephropathyDiabetes mellitusmedicineHumansDiabetic NephropathiesProspective StudiesDonor poolRetrospective StudiesTransplantationbusiness.industryGraft SurvivalSimultaneous pancreas kidney transplantationMiddle Agedmedicine.diseaseKidney TransplantationSurgeryTransplantationDiabetes Mellitus Type 1Treatment Outcomemedicine.anatomical_structureFemaleSurgeryPancreas TransplantationPancreasbusinessImmunosuppressive AgentsTransplantation Proceedings
researchProduct

Prognostic Significance of Creeping Proteinuria in the First Year After Transplantation.

2015

BACKGROUND Proteinuria changes have a prognostic significance in proteinuric nephropathies. Proteinuria has been related to kidney transplant outcomes, but there are no information about the impact of increasing proteinuria during the first year on long-term graft and patient survival. METHODS Retrospective cohort study of 591 kidney transplants to analyze the effect on long-term prognosis of: proteinuria at 3 (n = 591) and 12 (n = 583) months (no proteinuria: 150-299 mg/24 hours, 300-999 mg/24 hours, and ≥1 g/24 hours), and changes in proteinuria during the first year in such patients with proteinuria at 3 months (reduction ≥50% of proteinuria from 3 to 12 months, variation <50%, and incre…

AdultGraft RejectionMalemedicine.medical_specialtyTime FactorsPopulationUrologyurologic and male genital diseasesKidney Function TestsmedicineHumanseducationRetrospective StudiesTransplantationeducation.field_of_studyKidneyProteinuriaurogenital systembusiness.industryIncidenceHazard ratioGraft SurvivalRetrospective cohort studyMiddle Agedmedicine.diseasePrognosisKidney Transplantationfemale genital diseases and pregnancy complicationsConfidence intervalSurgeryTransplantationSurvival RateProteinuriamedicine.anatomical_structureSpainFemalemedicine.symptombusinessKidney diseaseFollow-Up StudiesTransplantation
researchProduct

Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release?

2012

Abstract Background Immunosuppressive therapy after orthotopic liver transplantation (OLT) requires a high degree of patient compliance to guarantee safety and avoid side effects. In 2007, prolonged-release tacrolimus was launched in Europe to improve compliance. In this prospective observational crossover single-center trial, we analyzed effects and side effects of prolonged-release tacrolimus in OLT patients. Methods LT patients at our center were included if they were older than l8 years of age, had had the procedure at least 6 months prior, and were outpatients currently on twice-daily tacrolimus. Patients were observed for 6 months before switching to once-daily tacrolimus. Patient his…

AdultGraft RejectionMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentChemistry Pharmaceuticalchemical and pharmacologic phenomenaLiver transplantationGastroenterologyTacrolimuschemistry.chemical_compoundPharmacotherapyDiabetes mellitusInternal medicineGermanymedicineHumansMedical historyProspective StudiesProspective cohort studyAgedTransplantationCross-Over Studiesbusiness.industryGraft SurvivalMiddle Agedmedicine.diseaseCrossover studyTacrolimusSurgeryLiver Transplantationsurgical procedures operativeTreatment OutcomechemistryDelayed-Action PreparationsSurgeryDrug Therapy CombinationFemaleGlycated hemoglobinbusinessImmunosuppressive AgentsTransplantation proceedings
researchProduct

Prevention of ischemic-type biliary lesions by arterial back-table pressure perfusion

2003

Abstract Ischemic-type biliary lesions (ITBLs) lead to considerable morbidity after orthotopic liver transplantation (OLT). The exact pathogenesis is unknown. We tested the hypothesis that insufficient perfusion of biliary arterial vessels might be responsible for ITBLs. This could be prevented by improved perfusion techniques. Since February 2000, we performed a controlled study using arterial back-table pressure perfusion (AP) to achieve reliable perfusion of the biliary-tract capillary system, which may be impaired by the high viscosity of University of Wisconsin solution. We retrospectively analyzed 190 OLTs performed between September 1997 and July 2002 with regard to ITBLs. One hundre…

AdultGraft Rejectionmedicine.medical_specialtyAdenosineOrthotopic liver transplantationAllopurinolmedicine.medical_treatmentOrgan Preservation SolutionsUrologyLiver transplantationPathogenesisPostoperative ComplicationsRaffinosePressuremedicineHumansInsulinViaspanAlanine aminotransferaseAgedRetrospective StudiesTransplantationHepatologyViscositybusiness.industryLiver DiseasesGraft SurvivalImmunosuppressionMiddle AgedGlutathioneStandard techniqueLiver TransplantationSurgeryPerfusionSurvival RateReperfusion InjurySurgeryBile DuctsbusinessPerfusionImmunosuppressive AgentsLiver Transplantation
researchProduct

Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alco…

2008

Hepatitis C virus (HCV)-related liver disease is enhanced by alcohol consumption. Of HCV-related liver transplantation (LT) recipients, 25% have a history of alcohol intake. The purpose of this research was to determine whether LT outcome differs between patients with cirrhosis of mixed etiology compared to HCV or alcohol alone. Of 494 LT (1997-2001), recipient/donor features, post-LT histological, metabolic complications [hypertension, diabetes-diabetes mellitus (DM)], and de novo tumors were compared in 3 groups [HCV-related cirrhosis = 170 (HCV group), alcohol-related cirrhosis (alcohol group) = 107, and cirrhosis of mixed etiology (mixed group) = 60]. Protocol biopsies were done in HCV …

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationmedicine.disease_causeGastroenterologyBody Mass IndexLiver diseasePostoperative ComplicationsLiver Cirrhosis AlcoholicInternal medicineHumansMedicineAgedTransplantationHepatologybusiness.industryIncidence (epidemiology)Graft Survivalvirus diseasesMiddle Agedmedicine.diseaseHepatitis Cdigestive system diseasesLiver TransplantationTreatment OutcomeHepatocellular carcinomaEtiologyFemaleSurgerybusinessBody mass indexImmunosuppressive AgentsLiver Transplantation
researchProduct

Functional characterization of hepatocytes for cell transplantation: customized cell preparation for each receptor.

2009

The first indication of hepatocyte transplantation is inborn liver-based metabolic disorders. Among these, urea cycle disorders leading to the impairment to detoxify ammonia and Crigler-Najjar Syndrome type I, a deficiency in the hepatic UDP-glucuronosyltransferase 1A1 present the highest incidence. Metabolically qualified human hepatocytes are required for clinical infusion. We proposed fast and sensitive procedures to determine their suitability for transplantation. For this purpose, viability, attachment efficiency, and metabolic functionality (ureogenic capability, cytochrome P450, and phase II activities) are assayed prior to clinical cell infusion to determine the quality of hepatocyt…

AdultMaleAdolescentCell SurvivalCell TransplantationCellBiomedical Engineeringlcsh:MedicineReceptors Cell SurfaceCell SeparationPharmacologyCold Ischemia TimeDonor Selectionchemistry.chemical_compoundYoung AdultmedicineHumansUreaGlucuronosyltransferaseReceptorChildUrea Cycle Disorders InbornCells CulturedAgedCrigler-Najjar SyndromeAged 80 and overTransplantationLiver DiseasesMetabolic disorderlcsh:RCold IschemiaGraft SurvivalInfant NewbornInfantCell BiologyMiddle Agedmedicine.diseaseTransplantationmedicine.anatomical_structurechemistryUrea cycleChild PreschoolUreaHepatocytesBiological AssayFemaleSteatosisCell transplantation
researchProduct

INFLUENCE OF ISLET TRANSPORTATION ON PANCREATIC ISLET ALLOTRANSPLANTATION IN TYPE 1 DIABETIC PATIENTS WITHIN THE SWISS-FRENCH GRAGIL NETWORK

2004

The influence of islet transportation on pancreatic islet allotransplantation in type 1 diabetic patients was evaluated within the GRAGIL network.From December 2001 to April 2003, 16 human pancreatic islet transplants were performed in 9 type 1 diabetic patients with an established kidney graft (functioning for at least 6 months) in four centers of the GRAGIL network. Islet isolation was performed in a core laboratory in Geneva, and the islet preparations were shipped by ambulance to each center for transplantation. One month after transplantation, the efficiency of the graft was assessed according to islet transportation time (ITT): ITT less than 2 hours (group 1, n=5), and ITT greater tha…

AdultMaleOncologyendocrine systemmedicine.medical_specialtyTime FactorsTissue and Organ Procurementendocrine system diseasesTissue and Organ Procurement/methodsmedicine.medical_treatmentIslets of Langerhans TransplantationTransportationHemoglobin A Glycosylated/metabolismInternal medicineImmunopathologymedicineHumansGlycated HemoglobinAutoimmune diseaseTransplantationType 1 diabetesgeographygeography.geographical_feature_categoryddc:617C-Peptidebusiness.industryGraft SurvivalIslets of Langerhans Transplantation/methods/physiologyCreatinine/bloodMiddle Agedmedicine.diseaseIsletTransplantationDiabetes Mellitus Type 1EndocrinologyDiabetes Mellitus Type 1/surgeryCreatinineC-Peptide/bloodFemaleFrancebusinessSwitzerlandAllotransplantationTransplantation
researchProduct

Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients…

2003

Patients with no prior chemotherapy and with advanced and progressive follicular lymphoma (FCL) or mantle cell lymphoma (MCL) were enrolled into a treatment protocol combining CHOP/rituximab-CHOP therapy with subsequent consolidation high-dose therapy (HDT) to evaluate the safety and feasibility of this treatment. Overall, 15 patients were enrolled and 13 patients completed the entire treatment protocol without major toxicities or increased infectious complications. One patient withdrew consent after achieving complete remission (CR) prior to HDT. One patient was taken off study with signs of disease progression after induction treatment. All patients showed stable engraftment after HDT. Re…

AdultMaleOncologymedicine.medical_specialtyLymphoma B-Cellmedicine.medical_treatmentFollicular lymphomaLymphoma Mantle-CellCHOPTransplantation AutologousAntibodies Monoclonal Murine-Derivedimmune system diseaseshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideImmunosuppression TherapyPeripheral Blood Stem Cell TransplantationTransplantationChemotherapybusiness.industryGraft SurvivalRemission InductionImmunityAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurvival AnalysisNon-Hodgkin's lymphomaSurgeryLymphomaTransplantationDoxorubicinVincristineFeasibility StudiesPrednisoneFemaleRadiotherapy AdjuvantMantle cell lymphomaRituximabRituximabbusinessmedicine.drugBone Marrow Transplantation
researchProduct

Long-Term Results After Liver Transplantation With “Livers That Nobody Wants” Within Eurotransplant: A Center's Experience

2008

Abstract Background Orthotopic liver transplantation (OLT) represents the only curative treatment for end-stage liver disease, but its application is limited because of organ shortages. The purpose of this study was to review the long-term outcomes after OLT during a 2-year period of 45 rescue offers organs within Eurotransplant. Patients and Methods Forty-five deceased donor liver allografts had been officially offered to and rejected by other transplantation centers 162 times prior to our acceptance. Data analysis addressed recurrence of primary disease, ischemic-type biliary lesions (ITBL), re-evaluation or relisting for OLT, re-OLT, as well as overall patient and graft survivals. Result…

AdultMaleReoperationmedicine.medical_specialtyOrthotopic liver transplantationmedicine.medical_treatmentLiver transplantationLiver diseaseCadavermedicineHumansTransplantation HomologousSurvivorsSurvival rateTransplantationbusiness.industryPatient SelectionGraft SurvivalHepatitis CLong term resultsMiddle Agedmedicine.diseaseTissue DonorsLiver TransplantationSurgerySurvival RateTransplantationTreatment Outcomesurgical procedures operativeFemaleSurgeryGraft survivalbusinessLiver FailureTransplantation Proceedings
researchProduct

Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell–depleted reduced-intensity transplantation

2006

AbstractAllogeneic hematopoietic stem cell transplantation (SCT) regimens incorporating the lymphocytotoxic CD52 antibody alemtuzumab demonstrate efficient engraftment and reduced graft-versus-host disease (GVHD). However, these protocols substantially impair posttransplantation antiviral and antitumor immunity. To accelerate immune reconstitution after alemtuzumab-based reduced-intensity SCT, we administered prophylactic CD8-depleted donor lymphocyte infusions (DLIs) starting on days 60 and 120 after transplantation. DLIs were processed in an immunomagnetic good manufacturing practice depletion procedure resulting in a 2.5- to 6-log reduction in CD8 T cells. Of 23 high-risk patients with h…

AdultMaleTransplantation ConditioningCD52Antibodies Neoplasmmedicine.medical_treatmentT cellImmunologyGraft vs Host DiseaseHematopoietic stem cell transplantationCD8-Positive T-LymphocytesAntibodies Monoclonal HumanizedImmunotherapy AdoptiveBiochemistryLymphocyte DepletionHLA AntigensmedicineHumansCytotoxic T cellAlemtuzumabPeripheral Blood Stem Cell TransplantationImmunomagnetic Separationbusiness.industryGraft SurvivalAntibodies MonoclonalCell BiologyHematologyMiddle AgedDonor Lymphocytesmedicine.diseaseTransplantationTreatment Outcomesurgical procedures operativeGraft-versus-host diseasemedicine.anatomical_structureHematologic NeoplasmsLangerhans CellsImmunologyAlemtuzumabFemaleK562 CellsbusinessFollow-Up Studiesmedicine.drugBlood
researchProduct